Diana Osorio
Department of Pediatrics, Division of Pediatrics
About Dr. Diana Osorio
Supports study design, generation of study protocol, clinical research forms, informed consent, Investigators Drug Brochure, Statistical Analysis Plan, and other study material, selection, and recruitment of investigational sites. Provides continuous medical monitoring during study conduct, answering site questions on inclusion/exclusion criteria or other protocol questions, evaluation of SAEs and AEs, review of laboratory and other patient’s data, review of codes for medical history, concomitant diseases and medications, adverse events, and provides medical expertise to project team during life-cycle of study. Assumes responsibility for ethical, e.g. medical, aspects of study. Leads and/or contributes to discussions with regulators and/or investigators, opinion leaders, internal and external clients, and project team support. Supports the feasibility group in developing feasibility plan and questionnaire, in determining type of investigational sites and in selecting countries and sites. Reviews feasibility results and report. Provides drug safety expertise for drugs, diagnostics, and devices in development and during market authorization. Reviews Safety Management Plans, evaluates adverse events and assesses regulatory reporting requirements, generates and/or reviews notification letters to regulators, investigators, IRBs and Ethic Committees. Reviews, analyzes and summarizes data for Data Monitoring Committees, generates and/or reviews Annual Safety Reports, protocol deviations and correspondence to health authorities, investigators, clients, and/or third parties. Evaluates benefits and risks of a medical compound/diagnostic and/or device including epidemiology of specific indication, natural course of disease, standard of care, alternate treatment options, develops Safety Development Plans, Pharmacovigilance Plans, Risk Management Programs including design and conduct of safety studies.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Pediatrics - Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Patient Care, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2007 | Universidad Central del Caribe, Puerto Rico, Bayamón, Puerto Rico, US, MD |
Postgraduate Training
| 2013-2014 | Postgraduate Fellow, Neuro-Oncology, New York University Langone Medical Center, New York, New York |
| 2010-2013 | Postgraduate Fellow, Hematology/Oncology, Northwell Health- Cohen Children’s Medical Center, New Hyde Park, New York |
| 2007-2010 | Resident, Pediatrics, Northwell Health- Cohen Children’s Medical Center, New Hyde Park, New York |
Board Certifications
| 2021 | American Board of Pediatrics Hematology Oncology |
| 2017 | American Board of Pediatrics |
Experience & Service
Academic Appointments
Medical Director, ICON, formerly PRA Health Sciences, Dublin, Leopardstown, 2021 - 2024
Assistant Professor, Department of Pediatrics, The Ohio State University, Colombus, Ohio, 2014 - 2021
Other Appointments/Responsibilities
Member, Society for Neuro-Oncology, MD Anderson Cancer Center, 2020 - Present
Member, Society for Neuro-Oncology, Nationwide Children's, 2013 - Present
Institutional Committee Activities
Member, MD Anderson IRB, 2024 - Present
Member, PNOC/CBTN Germ Cell Tumor Working Group, 2024 - Present
Member, Pediatric Clinical Practice Committee, 2024 - Present
Member, Pediatric Brain Tumor Consortium (PBTC) Ependymoma and Immunotherapy Committee, 2021 - Present
Member, Pacific Pediatric Neuro-Oncology Consortium (PNOC) CNS Germ Cell Tumor Working Group, 2021 - Present
Member, AACR-PLGAF Pediatric Brain Tumor Research Grants Scientific Review Committee, 2020 - Present
Member, Team Hope, 2016 - 2021
Member, CSRC, 2016 - 2021
Honors & Awards
| 2023 | Think Tank: Genetic Predisposition to Primary CNS Cancers |
Selected Publications
Peer-Reviewed Articles
- Oigman G, Gonzaga Y, Christiani M, Magalhaes D, Moreira V, Osorio DS, Ferman S. Survival of pediatric patients with ependymoma in a tertiary cancer center in Rio de Janeiro, Brazil. Front. Oncol, 2024. e-Pub 2024.
- Rajagopal R, Coronado RD, Hamid SA, del Campo RNM, Boop F, Bag A, Benito Reséndiz AE, Vasudeva Bhat K, Campos D, Chang K, Cirt R, Rahmartani LD, Foo JC, Hoveyan J, Lucas Jr JT, Ngcana T, Ain RU, Omran N, Osorio DS, Qureshi BM, Sabin ND, Schandorf E, Bankah P, Dadzie M, Gbadamos H, Sharafeldin H, Somathilaka M, Yang P, Jean-Jacques YA, Zhang A, Salman Z, Gonzalez M, Friedrich P, Rodriguez-Galindo C, Qaddoumi I, Moreira DC. Development of the pediatric neuro-oncology services assessment aid: An assessment tool for pediatric neuro-oncology service delivery capacity. NOA 6(1), 2024.
- Giro´ n AV, Blanco-Lopez J, Calderon P, Jiron R, Pineda E, Montero M, Lizardo Y, Bartels U, Osorio DS. Primary central nervous system germ cell tumors in Central America and the Caribbean Region: an AHOPCA 20-year experience. Front. Oncol, 2024. e-Pub 2024.
- Osorio DS, Yankelevich M, Zaky WT, Lafay-Cousin L, Margol AS, Toll S, Quiroz L, Fox JE, Hanson D, Gardner SL, Prados M, Mueller S, L Finlay AJ. Marrow-ablative consolidation chemotherapy (HDCT) to decrease the development of choroid plexus carcinoma (CPC) specific relapse in high-risk TP53-mutated (germline or somatic) young children with newly diagnosed CPC. JCO 42(16), 2024. e-Pub 2024.
- Salceda-Rivera V, Tejocote-Romero I, Osorio DS, Bellido-Magaña R, Lo´ pez-Facundo A, Anaya-Aguirre SE, Ortiz-Morales D, Rivera-Luna R, Reyes-Gutie´ rrez E, Rivera-Go´ mez R, Velasco-Hidalgo L, Corte´ s-Alva D, Lagarda-Arrechea S, Arregu´ın-Gonza´lez FE, Benito-Rese´ ndiz AE, Cha´ vez-Gallegos S, Pe´rez-Rivera E, Gayta´ n-Ferna´ ndez GJ, Leo´ n-Espitia JA, Dom´ınguez-Sa´ nchez J, Leal-Cavazos C, Simo´ n-Gonza´lez C, Larios-Farak TC, Mac´ıas-Garc´ıa NA, Garc´ıa-Espinosa AC, Guerrero-Maymes F, Casillas-Toral P, Gonza´lez-Ramella O. Impact of treatment and clinical characteristics on the survival of children with medulloblastoma in Mexico. Front. Oncol 14, 2024. e-Pub 2024.
Editorials
- Osorio, DS, Qaddoumi, I, Moreira, DC. Editorial. Frontiers in Oncology 15, 2025. PMID: 39931086.
Selected Presentations & Talks
Local Presentations
- 2024. “Brain Tumors in Neurofibromatosis”. Invited. Texas Neurofibromatosis Foundation Symposium. Houston, Texas, US.
- 2024. Peds NeurOonc future clinical trials at MDA. Invited. Energy Transfer’s Fundraising Campaign Event. Houston, Texas, US.
International Presentations
- 2024. News in the Management of Germ Cell Tumors in Pediatric Patients. Invited. 42nd National and 11th International Congress of Oncology of the Mexican Society of Oncology, US.
- 2023. Pediatric Neuro-oncology in the New Molecular Era. Invited. Mexican Association of Pediatric OncoHematology (AMOHP), US.
- 2021. Medulloblastoma Treatment Guidelines in Central America. Invited. 23rd annual Association of Pediatric Hematology Oncology in Central America, US.
- 2020. Addressing Global and Loco-Regional Disparities in the Management of Childhood Brain Cancer. Invited. Pediatric Grand Rounds Nationwide Children’s Hospital, US.
- 2020. Directed Medulloblastoma Treatment Guidelines in Central America. Invited. 22nd annual Association of Pediatric Hematology Oncology in Central America, US.
- 2019. Management of Infant and Childhood Medulloblastoma and the Management of Ependymoma. Invited. 8th Annual Latin American Pediatric Neurosurgery Conference, US.
- 2018. Pediatric Neuro-Oncology Pertinent to Low-to-Middle Income Countries (LMIC). Invited. Co-organizing committee member and 3rd PLANO educational conference at INEN, US.
- 2018. Association of Pediatric Hematology/Oncology of Colombia (ACHOP), Regional conference. Ependymoma and Medulloblastoma. Invited, US.
- 2018. Management of Medulloblastoma, Craniopharyngioma and Central Nervous System Germ Cell Tumors. Leo Messi Foundation Neuro-oncology Course. Invited, US.
- 2017. Experiencia de un grupo de discusión interactivo Latino Americano en tumores del SNC. Latin American Society of Pediatric Oncology (SLAOP). Invited, US.
- 2016. Pediatric Brain Tumors Session, Session Organizer and Moderator: Pediatric Brain Tumor Patient Cases and Discussion of their Management, Association of Pediatric Hematology/Oncology Central America. Invited, US.
- 2015. First International Pediatric Latin American Neurooncology (PLANO) at GRACC Institute; Management of Low Grade Gliomas and Management of ATRT/PNET. Invited, US.
- 2013. Prevalence of elevated erythrocyte adenosine deaminase activity, a marker for Diamond Blackfan Anemia in patients with congenital heart disease. Poster. American Society of Peditaric Hematology Oncology, US.
- 2013. Dasatinib in children and adolescents with central nervous system germ cell tumors. Poster. Third International CNS Germ Cell Tumor Symposium, US.
- 2009. Irradiation-avoiding strategies in the management of young children with newly diagnosed central nervous system embryonal tumors: 18 years of three serial chemotherapy regimens – the “Head Start” Protocols. Invited. Thirty-fifth Annual Meeting of the Korean Cancer Society, US.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | Phase II Trial Evaluating Chemotherapy Followed by Response- Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas |
| Funding Source: | COG |
| Role: | Co-PI |
| ID: | ACNS2321 |
| Date: | 2025 - Present |
| Title: | Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations |
| Funding Source: | NCI |
| Role: | Co-PI |
| ID: | ACNS1931 |
| Date: | 2025 - Present |
| Title: | DIPG/DMG Psychosocial Support: Grief-informed interventions to bolster meaning and reduce emotional distress |
| Funding Source: | Children's Brain Tumor Foundation |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations |
| Funding Source: | ACNS |
| Role: | Co-PI |
| Date: | 2024 - Present |
| Title: | A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas |
| Funding Source: | ACNS |
| Role: | Co-PI |
| Date: | 2024 - Present |
| Title: | FIREFLY-2 |
| Funding Source: | Day One Biopharmaceuticals, Inc |
| Role: | PI |
Patient Reviews
CV information above last modified April 03, 2025